Enzo Biochem, Inc. (ENZ) Position Boosted by ClariVest Asset Management LLC

ClariVest Asset Management LLC raised its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 32.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 266,320 shares of the medical research company’s stock after buying an additional 64,543 shares during the period. ClariVest Asset Management LLC owned about 0.57% of Enzo Biochem worth $2,941,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ENZ. American International Group Inc. raised its position in shares of Enzo Biochem by 7.1% in the first quarter. American International Group Inc. now owns 24,432 shares of the medical research company’s stock valued at $204,000 after buying an additional 1,610 shares during the period. Bank of New York Mellon Corp raised its position in shares of Enzo Biochem by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 206,447 shares of the medical research company’s stock valued at $1,728,000 after buying an additional 2,409 shares during the period. Campbell & CO Investment Adviser LLC raised its position in shares of Enzo Biochem by 24.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 14,325 shares of the medical research company’s stock valued at $120,000 after buying an additional 2,812 shares during the period. Rhumbline Advisers raised its position in shares of Enzo Biochem by 10.6% in the second quarter. Rhumbline Advisers now owns 49,252 shares of the medical research company’s stock valued at $544,000 after buying an additional 4,720 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC raised its position in shares of Enzo Biochem by 0.9% in the first quarter. Gilder Gagnon Howe & Co. LLC now owns 831,354 shares of the medical research company’s stock valued at $6,958,000 after buying an additional 7,401 shares during the period. 62.90% of the stock is currently owned by hedge funds and other institutional investors.

Enzo Biochem, Inc. (NYSE ENZ) opened at 11.08 on Thursday. The stock’s 50 day moving average price is $11.26 and its 200-day moving average price is $9.06. Enzo Biochem, Inc. has a 12 month low of $4.88 and a 12 month high of $12.04. The firm has a market capitalization of $514.19 million, a price-to-earnings ratio of 15.54 and a beta of 0.97.

COPYRIGHT VIOLATION NOTICE: “Enzo Biochem, Inc. (ENZ) Position Boosted by ClariVest Asset Management LLC” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/08/17/enzo-biochem-inc-enz-position-boosted-by-clarivest-asset-management-llc.html.

Several brokerages have issued reports on ENZ. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday. BidaskClub lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Monday.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply